Fo­cused on the cell ther­a­py man­u­fac­tur­ing bot­tle­neck, Cel­lares tur­bocharges plans for 'shut­tle' tech

When Cel­lares CEO and co-founder Fabi­an Ger­ling­haus tore his ACL a few years ago, he was brought out­side of a Bay Area hos­pi­tal to the park­ing lot where he re­ceived an MRI in­side a truck. He and his col­leagues hope that the same can be done for cell ther­a­py — one day — and they just re­ceived $82 mil­lion in fund­ing to help do so.

Cel­lares on Wednes­day bagged a Se­ries B round, bring­ing its to­tal fund­ing to $100 mil­lion so far. Those funds will be used to de­vel­op the Cell Shut­tle, a portable fac­to­ry that Cel­lares hopes will dis­rupt the ex­pen­sive and lo­gis­ti­cal­ly com­pli­cat­ed cell ther­a­py man­u­fac­tur­ing process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER